Ian L. Linde

1.1k total citations · 1 hit paper
11 papers, 458 citations indexed

About

Ian L. Linde is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Ian L. Linde has authored 11 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Ian L. Linde's work include Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (4 papers) and Virus-based gene therapy research (3 papers). Ian L. Linde is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (4 papers) and Virus-based gene therapy research (3 papers). Ian L. Linde collaborates with scholars based in United States, South Africa and India. Ian L. Linde's co-authors include Edgar G. Engleman, Tyler R. Prestwood, Yaron Carmi, Bryan M. Burt, Matthew H. Spitzer, Nupur Bhattacharya, Matthew G. Davidson, Nicola Perlman, Ganesh V. Pusapati and Justin A. Kenkel and has published in prestigious journals such as Nature, Cancer Cell and Cancer Research.

In The Last Decade

Ian L. Linde

11 papers receiving 451 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutrophil-activating therapy for the treatment of cancer

2023 117 citations Ian L. Linde, Tyler R. Prestwood et al. Cancer Cell profile →

Peers

Ian L. Linde

IMMUN

ONCOL

MB

BE

RNMI

Heinke Conrad Germany

Stina L. Wickström Sweden

Wout de Mey Belgium

Frederike A. Hartl Germany

Annelisa M. Cornel Netherlands

Tania Rodríguez-Cruz United States

Nicolas Acquavella United States

Liaomin Peng United States

Heinke Conrad Germany

Ian L. Linde

238 ×0.8

IMMUN

269 ×1.2

ONCOL

150 ×0.9

MB

24 ×0.4

BE

44 ×1.1

RNMI

Citations per year, relative to Ian L. Linde Ian L. Linde (= 1×) peers Heinke Conrad

Countries citing papers authored by Ian L. Linde

Since Specialization

Citations

This map shows the geographic impact of Ian L. Linde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian L. Linde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian L. Linde more than expected).

Fields of papers citing papers by Ian L. Linde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian L. Linde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian L. Linde. The network helps show where Ian L. Linde may publish in the future.

Co-authorship network of co-authors of Ian L. Linde

This figure shows the co-authorship network connecting the top 25 collaborators of Ian L. Linde. A scholar is included among the top collaborators of Ian L. Linde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian L. Linde. Ian L. Linde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Goddard, Erica T., Miles H. Linde, Shivani Srivastava, et al.. (2024). Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 42(1). 119–134.e12. 29 indexed citations

2.

Linde, Miles H., Amy C. Fan, Thomas Köhnke, et al.. (2023). Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy. Cancer Discovery. 13(5). 1164–1185. 33 indexed citations

3.

Linde, Ian L., Tyler R. Prestwood, Jingtao Qiu, et al.. (2023). Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 41(2). 356–372.e10. 117 indexed citations breakdown →

4.

Netanely, Dvir, Ron Shamir, Rachel Blau, et al.. (2020). Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. Cancer Research. 80(10). 1942–1956. 25 indexed citations

5.

Tang, Rui, Ian L. Linde, Nicholas J. Kramer, et al.. (2020). A versatile system to record cell-cell interactions. eLife. 9. 32 indexed citations

6.

Reticker-Flynn, Nathan E., Weiruo Zhang, Pamela A. Basto, et al.. (2020). Lymph Node Colonization Alters the Systemic Immune Response to Enable Metastasis to Distant Tissues. SSRN Electronic Journal. 1 indexed citations

7.

Carmi, Yaron, Tyler R. Prestwood, Matthew H. Spitzer, et al.. (2016). Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight. 1(18). e89020–e89020. 20 indexed citations

8.

Linde, Ian L., et al.. (2016). Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes. Scientific Reports. 6(1). 36610–36610. 13 indexed citations

9.

Linde, Ian L., et al.. (2016). 6. Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-Oncogenes. Molecular Therapy. 24. S3–S4. 6 indexed citations

10.

Carmi, Yaron, Matthew H. Spitzer, Ian L. Linde, et al.. (2015). Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 521(7550). 99–104. 170 indexed citations

11.

Adair, Jennifer E., Ian L. Linde, Patty Trobridge, et al.. (2015). Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection. Gene Therapy. 22(7). 591–595. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact